Table S1 Transcripts Up-Regulated in melan-a Mela- nocytes Following 5-aza-29-deoxycytidine Treatment Identified by Genome-Wide Screening. (DOC) Table S2 Transcripts Up-Regulated in 4C Pre-Malig- nant Melanocytes Following 5-aza-29-deoxycytidine Treatment Identified by Genome-Wide Screening. (DOC) Table S3 Transcripts Up-Regulated in 4C112 Non- Metastatic Melanoma Cells Following 5-aza-29-deoxycy- tidine Treatment Identified by Genome-Wide Screening. (DOC) Table S4 Transcripts Up-Regulated in 4C11+ Metastat- ic Melanoma Cells Following 5-aza-29-deoxycytidine Treatment Identified by Genome-Wide Screening. (DOC) Primers Used for Amplification by RT-qPCR. Table S5 (DOC) References 1. Soengas MS, Lowe SW (2003) Apoptosis and melanoma chemoresistance. Oncogene 22: 3138–3151. 2. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, et al. (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27: 6199–6206. 3. Vidwans SJ, Flaherty KT, Fisher DE, Tenenbaum JM, Travers MD, et al. (2011) A melanoma molecular disease model. PLoS One 6: e18257. 4. Souza CF, Morais AS, Jasiulionis MG (2012) Biomarkers as key contributors in treating malignant melanoma metastases. Dermatol Res Pract 156068. 5. Hoek KS, Goding CR (2010) Cancer stem cells versus phenotype-switching in melanoma. Pigment Cell Melanoma Res 23: 746–759. 6. Jaenisch R, Bird A (2003) Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet33 Suppl: 245– 254. 7. Fraga MF, Ballestar E, Paz MF, Ropero S, Setien F, et al. (2005) Epigenetic differences arise during the lifetime of monozygotic twins. Proc Natl Acad Sci USA 102: 10604–10609. 8. Seftor EA, Meltzer PS, Kirschmann DA, Margaryan NV, Seftor RE, et al. (2006) The epigenetic reprogramming of poorly aggressive melanoma cells by a metastatic microenvironment. J Cell Mol Med 10: 174–196. 9. Utikal J, Maherali N, Kulalert W, Hochedlinger K (2009) Sox2 is dispensable for the reprogramming of melanocytes and melanoma cells into induced pluripotent stem cells. J Cell Sci 122: 3502–3510. 10. Costa FF, Seftor EA, Bischof JM, Kirschmann DA, Strizzi L, et al. (2009) Epigenetically reprogramming metastatic tumor cells with an embryonic microenvironment. Epigenomics 1: 387–398. 11. Molognoni F, Cruz AT, Meliso FM, Morais AS, Souza CF, et al. (2011) Epigenetic reprogramming as a key contributor to melanocyte malignant transformation. Epigenetics 6: 450–464. 12. Baylin SB, Jones PA (2011) A decade of exploring the cancer epigenome – biological and translational implications. Nat Rev Cancer 11: 726–734. 13. Szyf M (2009) Epigenetics, DNA methylation, and chromatin modifying drugs. Annu Rev Pharmacol Toxicol 49: 243–263. 14. Bennett DC, Cooper PJ, Hart IR (1987) A line of non-tumorigenic mouse melanocytes, syngeneic with the B16 melanoma and requiring a tumour promoter for growth. Int J Cancer 39: 414–418. 15. Oba-Shinjo SM, Correa M, Ricca TI, Molognoni F, Pinhal MA, et al. (2006) Melanocyte transformation associated with substrate adhesion impediment. Neoplasia 8: 231–241. 16. Roschke AV, Lababidi S, Tonon G, Gehlhaus KS, Bussey K, et al. (2005) Karyotypic ‘‘state’’ as a potential determinant for anticancer drug discovery. Proc Natl Acad Sci USA 102: 2964–2969. 17. Silva AG, Graves HA, Guffei A, Ricca TI, Mortara RA, et al. (2010) Telomere- centromere-driven genomic instability contributes to Karyotype evolution in a mouse model of melanoma. Neoplasia 12: 11–19. 18. Gallagher WM, Bergin OE, Rafferty M, Kelly ZD, Nolan IM, et al. (2005) Multiple markers for melanoma progression regulated by DNA methylation: insights from transcriptomic studies. Carcinogenesis 26: 1856–1867. 19. Bolden JE, Peart MJ, Johnstone RW (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5: 769–784. 20. Aldrian S, Trautinger F, Fro¨hlich I, Berger W, Micksche M, et al. (2002) Overexpression of Hsp27 affects the metastatic phenotype of human melanoma cells in vitro. Cell Stress Chaperones 7: 177–185. 21. Aldrian S, Kindas-Mu¨gge I, Trautinger F, Fro¨hlich I, Gsur A, et al. (2003) Overexpression of Hsp27 in a human melanoma cell line: regulation of E- Novel Candidate Biomarkers in Melanomas Acknowledgments The authors would like to thank Dr Daniela Fillipini Ierardi for her assistance in standardization of primer concentration for RT-qPCR and Prof. Francisco Bosco for some comments about Statistics as well. We also thank Prof. Silvya Stuchi-Maria Engler (Departamento de Ana´lises Cl´ınicas e Toxicolo´gicas, Universidade de Sa˜o Paulo) and Dr. Linda Maximiano (Hospital Universita´rio, Universidade de Sa˜o Paulo) for providing the human primary melanocytes. We also thank the Associac¸a˜o Fundo de Incentivo a` Psicofarmacologia (AFIP, Sa˜o Paulo, Brazil) for the use of Affymetrix Platform. We would like to thank Universidade Federal de Sa˜o Paulo and Coordenac¸ a˜o de Aperfeic¸oamento de Pessoal de N´ıvel Superior. This work was supported by the Fundac¸ a˜o de Amparo a` Pesquisa do Estado de Sa˜o Paulo [09/51462-9 to C.F.S. & 06/61293-1 and 11/ 12306-1 to M.G.J.]. Author Contributions Conceived and designed the experiments: CFS MGJ. Performed the experiments: CFS PX ACM AGS DCS. Analyzed the data: CFS MGJ. Contributed reagents/materials/analysis tools: CFS PX AGS SM VB JDL MGJ. Wrote the paper: CFS MGJ. cadherin, MUC18/MCAM, and plasminogen activator (PA) system. Cell Stress Chaperones 8: 249–257. 22. Lassmann S, Weis R, Makowiec F, Roth J, Danciu M, et al. (2007) Array CGH identifies distinct DNA copy number profiles of oncogenes and tumor suppressor genes in chromosomal-and microsatellite-unstable sporadic colorectal carcino- mas. J Mol Med (Berl) 85: 293–304. 23. Steele N, Finn P, Brown R, Plumb JA (2009) Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo. Br J Cancer 100: 758–763. 24. Cedar H, Bergman Y (2009) Linking DNA methylation and histone modification: patterns and paradigms. Nat Rev Genet 10: 295–304. 25. Mossman D, Scott RJ (2011) Long term transcriptional reactivation of epigenetically silenced genes in colorectal cancer cells requires DNA hypomethylation and histone acetylation. PLoS ONE 6: e23127. 26. Ithychanda SS, Das M, Ma YQ, Ding K, Wang X, et al. (2009) Migfilin, a molecular switch in regulation of integrin activation. J Biol Chem 284: 4713– 4722. 27. Kim A, Yang Y, Lee MS, Yoo YD, Lee HG, et al. (2008) NDRG2 gene expression in B16F10 melanoma cells restrains melanogenesis via inhibition of Mitf expression. Pigment Cell Melanoma Res 21: 653–664. 28. Kim A, Kim MJ, Yang Y, Kim JW, Yeom YI, et al. (2009) Suppression of NF- kappaB activity by NDRG2 expression attenuates the invasive potential of highly malignant tumor cells. Carcinogenesis 30: 927–936. 29. Slominski A, Tobin DJ, Shibahara S, Wortsman J (2004) Melanin pigmentation in mammalian skin and its hormonal regulation. Physiol Rev 84: 1155–1228. 30. Brozyna AA, Jozwicki W, Janjetovic Z, Slominski AT (2011) Expression of vitamin D receptor decreases during progression of pigmented skin lesions. Hum Pathol 42: 618–631. 31. Mendes-Pereira AM, Sims D, Dexter T, Fenwick K, Assiotis I, et al. (2012) Genome-wide functional screen identifies a compendium of genes affecting sensitivity to tamoxifen. Proc Natl Acad Sci USA 109: 2730–2735. 32. Meeran SM, Patel SN, Tollefsbol TO (2010) Sulforaphane causes epigenetic repression of hTERT expression in human breast cancer cell lines. PLoS ONE 5: e11457. 33. Vergani E, Vallacchi V, Frigerio S, Deho P, Mondellini P, et al. (2011) Identification of MET and SRC activation in melanoma cell lines showing primary resistance to PLX4032. Neoplasia 13: 1132–1142. 34. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, et al. (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363: 711–723. 35. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, et al. (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364: 2507–2516. 36. Slominski A, Wortsman J (2000). Neuroendocrinology of the skin. Endocr Rev 21: 457–487. 37. Slominski A (2009) Neuroendocrine activity of the melanocyte. Exp Dermatol 18: 760–763. 38. Nishimura EK, Suzuki M, Igras V, Du J, Lonning S, et al. (2010) Key roles for transforming growth factor beta in melanocyte stem cell maintenance. Cell Stem Cell 6: 130–140. 39. Moriyama M, Osawa M, Mak SS, Ohtsuka T, Yamamoto N, et al. (2006) Notch signaling via Hes1 transcription factor maintains survival of melanoblasts and melanocyte stem cells. J Cell Biol 173: 333–339. 40. Ohm JE, McGarvey KM, Yu X, Cheng L, Schuebel KE, et al. (2007) A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA PLOS ONE | www.plosone.org 18 September 2012 | Volume 7 | Issue 9 | e44800